BCL2 and prostate carcinoma: Additionally, in prostate cancer it has been shown that NOTCH1 silencing decreased BCL-2 levels which increased sensitivity to chemotherapy [78], suggesting a similar mechanism for the interplay of AZ1 and venetoclax.